ESR1 and cancer: In ERα-positive cancer cells, ERβ is also capable of interfering with ERα activity through hetero-dimerization and/or competition for common binding sites [6, 14, 15, 20–30], thus making ERβ a partial dominant negative receptor for ERα [23, 24, 31].